Pneumococcal vaccination among adults with chronic respiratory diseases: a historical overview

References

• Ortqvist A, Hedlund J, Kalin M. Streptococcus pneumoniae: epidemiology, risk factors, and clinical features. Semin. Respir. Crit. Care Med.26, 563–574 (2005).
   PubMed Web of Science ®Google Scholar
• Kyaw MH, Rose CE Jr, Fry AM et al. The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. J. Infect. Dis.192, 377–386 (2005).
   PubMed Web of Science ®Google Scholar
• Kalin M, Örtqvist A, Almela M et al. Prospective study of prognostic factors in community-acquired bacteremic pneumococcal disease in 5 countries. J. Infect. Dis.182, 840–847 (2000).
   PubMed Web of Science ®Google Scholar
• Baddour LM, Yu VL, Klugman KP et al. International Pneumococcal Study Group. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am. J. Respir. Crit. Care Med.170, 440–444 (2004).
   PubMed Web of Science ®Google Scholar
• Feikin DR, Schuchat A, Kolczak M et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995–1997. Am. J. Public Health90, 223–229 (2000).
   PubMed Web of Science ®Google Scholar
• Torres A, Dorca J, Zalacaín R et al. Community-acquired pneumonia in chronic obstructive pulmonary disease. A Spanish multicenter study. Am. J. Respir. Crit. Care Med.154, 1456–1461 (1996).
   PubMed Web of Science ®Google Scholar
• Nuorti JP, Butler JC, Farley MM et al. The Active Bacterial Core Surveillance Team. Cigarette smoking and invasive pneumococcal disease. N. Engl. J. Med.342, 681–689 (2000).
   PubMed Web of Science ®Google Scholar
• COPD Guidelines Group of the Standards of Care Committee of the BTS. BTS guidelines for the management of chronic obstructive pulmonary disease. Thorax52, S7–S15 (1997).
   Web of Science ®Google Scholar
• Mandell LA, Wunderink RG, Anzueto A et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis.44(Suppl. 2), S27–S72 (2007).
   PubMed Web of Science ®Google Scholar
• Murtagh E, Heaney L, Gingles J et al. Prevalence of obstructive lung disease in a general population sample: the NICECOPD study. Eur. J. Epidemiol.20, 443–453 (2005).
   PubMed Web of Science ®Google Scholar
• Gaillat J. Should patients with chronic obstructive pulmonary disease be vaccinated against pneumococcal diseases? Expert Rev. Respir. Med.3(6), 585–596 (2009).
   PubMedGoogle Scholar
• National Heart, Lung and Blood Institute. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NIH Publication No. 2701. National Heart, Lung and Blood Institute, Bethesda, MD, USA (2001).
   Google Scholar
• Jackson L, Neuzil K, Yu O et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N. Engl. J. Med.348(18), 1747–1755 (2003).
   PubMed Web of Science ®Google Scholar
• Vila-Corcoles A, Ochoa-Gondar O, Hospital I et al. Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study. Clin. Infect. Dis.43, 860–868 (2006).
   PubMed Web of Science ®Google Scholar
• Ochoa-Gondar O, Vila-Corcoles A, Ansa X et al. Effectiveness of pneumococcal vaccination in older adults with chronic respiratory diseases: results of the EVAN-65 study. Vaccine26, 1955–1962 (2008).
   PubMed Web of Science ®Google Scholar
• Lieberman D, Gelfer Y, Varshavsky R, Dvoskin B, Leinonen M, Friedman MG. Pneumonic vs nonpneumonic acute exacerbations of COPD. Chest122(4), 1264–1270 (2002).
   PubMed Web of Science ®Google Scholar
• Restrepo MI, Mortensen EM, Pugh JA, Anzueto A. COPD is associated with increased mortality in patients with community-acquired pneumonia. Eur. Resp. J.28, 346–351 (2008).
   Web of Science ®Google Scholar
• Ko FW, Ip M, Chan PK, Ng SS, Chau SS, Hui DS. A one year-prospective study of infectious etiology in patients hospitalized with acute exacerbations of COPD and concomitant pneumonia. Resp. Med.102, 1109–1116 (2008).
   PubMed Web of Science ®Google Scholar
• Alfageme I, Vazquez R, Reyes N et al. Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Thorax61, 189–195 (2006).
   PubMed Web of Science ®Google Scholar
• Molinos L, Clemente MG, Miranda B et al. ASTURPAR Group. Community-acquired pneumonia in patients with and without chronic obstructive pulmonary disease. J. Infect.58(6), 417–424 (2009).
   PubMed Web of Science ®Google Scholar
• National Institute of Clinical Excellence. COPD: national clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax59(Suppl. 1), S181–S272 (2004).
   PubMed Web of Science ®Google Scholar
• Papi A, Bellettato CM, Braccioni F et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am. J. Respir. Crit. Care Med.173(10), 1114–1121 (2006).
   PubMed Web of Science ®Google Scholar
• Sethi S. Infectious etiology of acute exacerbations of chronic bronchitis. Chest117(Suppl. 2), S380–S385 (2000).
   PubMed Web of Science ®Google Scholar
• Saint S, Flaherty KR, Abrahamse P, Martinez FJ, Fendrick AM. Acute exacerbation of chronic bronchitis: disease-specific issues that influence the cost–effectiveness of antimicrobial therapy. Clin. Ther.23, 499–512 (2001).
   PubMed Web of Science ®Google Scholar
• Bogaert D, Van der Valk P, Ramdin R et al. Host–pathogen interaction during pneumococcal infection in patients with chronic obstructive pulmonary disease. Infect. Immun.72(2), 818–823 (2004).
   PubMed Web of Science ®Google Scholar
• Black PN, McDonald CF. Interventions to reduce the frequency of exacerbations of chronic obstructive pulmonary disease. Postgrad. Med. J.85(1001), 141–147 (2009).
   PubMed Web of Science ®Google Scholar
• Varkey JB, Varkey AB, Varkey B. Prophylactic vaccinations in chronic obstructive pulmonary disease: current status. Curr. Opin. Pulm. Med.15(2), 90–928 (2009).
   PubMed Web of Science ®Google Scholar
• Poole PJ, Chacko E, Wood-Baker RW, Cates CJ. Influenza vaccine for patients with chronic obstructive pulmonary disease (Cochrane review). Cochrane Database Syst. Rev.4, CD002733 (2009).
   Google Scholar
• Centers for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practice (ACIP). MMWR Morb. Mortal. Wkly Rep.46(RR-8), 1–24 (1997).
   PubMedGoogle Scholar
• Hausdorff WP, Feikin DR, Klugman KP. Epidemiological differences among pneumococcal serotypes. Lancet Infect. Dis.5, 83–93 (2005).
   PubMed Web of Science ®Google Scholar
• Fedson DS, Musher DM. Pneumococcal polysaccharide vaccine. In: Vaccines (4th Edition). Plotkin SA, Orenstein WA (Eds). Saunders, PA, USA, 529–588 (2003).
   Google Scholar
• Abraham-Van Parijs B. Review of pneumococcal conjugate vaccine in adults: implications on clinical development. Vaccine22, 1362–1371 (2004).
   PubMed Web of Science ®Google Scholar
• Tai SS. Streptococcus pneumoniae protein vaccine candidates: properties, activities and animal studies. Crit. Rev. Microbiol.32, 139–153 (2006).
   PubMed Web of Science ®Google Scholar
• Watson DA, Musher DM. A brief history of the pneumococcus in biomedical research. Semin. Respir. Infect.14(3), 198–208 (1999).
   PubMedGoogle Scholar
• Felton L, Baily G. Biologic significance of the soluble specific substance of pneumococci. J. Infect. Dis.38, 131–144 (1926).
   Google Scholar
• Smillie W, Warnock G, White H. A study of a type I pneumococcus epidemic at the state hospital in Worcester, MA. Am. J. Public Health28, 293– 302 (1938).
   Google Scholar
• Kaufman P. Pneumonia in old age: active immunization against pneumonia with pneumococcus polysaccharide: results of a six year study. Arch. Intern. Med.79, 518–531 (1947).
   Google Scholar
• Austrian R. Pneumococcus: the first one hundred years. Rev. Infect. Dis.3(2), 183–189 (1981).
   PubMedGoogle Scholar
• Smit P, Oberholzer D, Hayden-Smith S, Koornhof H, Hilleman M. Protective efficacy of pneumococcal polysaccharide vaccines. JAMA238, 2613–2616 (1977).
   PubMed Web of Science ®Google Scholar
• Austrian R, Douglas RM, Schiffman G et al. Prevention of pneumococcal pneumonia by vaccination. Trans. Assoc. Am. Physic.89, 184–194 (1976).
   PubMedGoogle Scholar
• Sankilampi U, Honkanen PO, Bloigu A, Herva E, Leinonen M. Antibody response to pneumococcal capsular polysaccharide vaccine in the elderly. J. Infect. Dis.173, 387–393 (1996).
   PubMed Web of Science ®Google Scholar
• Artz AS, Ershler WB, Longo DL. Pneumococcal vaccination and revaccination of older adults. Clin. Microbiol. Rev.16, 308–318 (2003).
   PubMed Web of Science ®Google Scholar
• Musher DM, Manoff SB, McFetridge RD et al. Antibody persistence ten years after first and second doses of 23-valent pneumococcal polysaccharide vaccine, and immunogenicity and safety of second and third doses in older adults. Hum. Vaccin.7, 919–928 (2011).
   PubMed Web of Science ®Google Scholar
• Leech JA, Gervais A, Ruben FL. Efficacy of pneumococcal vaccine in severe chronic obstructive pulmonary disease. CMAJ136, 361–365 (1987).
   PubMed Web of Science ®Google Scholar
• Musher D, Luchi MJ, Watson DA, Hamilton R, Baughn RE. Pneumococcal polysaccharide vaccine in young adults and olders bronchitics: determination of IgG responses by ELISA and the effect of adsorption of serum with non-type-specific cell wall polysaccharide. J. Infect. Dis.161, 728–735 (1990).
   PubMed Web of Science ®Google Scholar
• Rubins JB, Puri AK, Loch J et al. Magnitude, duration, quality and function of pneumococcal vaccine responses in elderly adults. J. Infect. Dis.178, 431–440 (1998).
   PubMed Web of Science ®Google Scholar
• Chen M, Hisatomi Y, Furumoto A et al. Comparative immune responses of patients with chronic pulmonary diseases during the 2-year period after pneumococcal vaccination. Clin. Vaccin. Immunol.14(2), 139–145 (2007).
   PubMedGoogle Scholar
• Davis A, Aranda CP, Schiffman G, Christianson LC. Pneumococcal infection and immunologic response to pneumococcal vaccine in chronic obstructive pulmonary disease. Chest92(22), 204–212 (1987).
   PubMed Web of Science ®Google Scholar
• Lai CC, Lee LN, Yu CJ et al. Antibody responses to pneumococcal polysaccharide vaccine in Taiwanese patients with chronic obstructive pulmonary disease. J. Formos Med. Assoc.106(3), 196–203 (2007).
   PubMed Web of Science ®Google Scholar
• Steentoft J, Konradsen HB, Hilskov J, Gislason G, Andersen JR. Response to pneumococcal vaccine in chronic obstructive lung disease: the effect of ongoing, systemic steroid treatment. Vaccine24, 1408–1412 (2006).
   PubMed Web of Science ®Google Scholar
• Klemets P, Lyytikäinen O, Ruutu P et al. Risk of invasive pneumococcal infections among working age adults with asthma. Thorax65(8), 698–702 (2010).
   PubMed Web of Science ®Google Scholar
• Jung JA, Kita H, Dhillon R et al. Influence of asthma status on serotype-specific pneumococcal antibody levels. Postgrad. Med.122(5), 116–124 (2010).
   PubMed Web of Science ®Google Scholar
• Fine MJ, Smith MA, Carson CA et al. Efficacy of pneumococcal vaccination in adults. A meta-analysis of randomized controlled trials. Arch. Intern. Med.154, 2666–2677 (1994).
   PubMed Web of Science ®Google Scholar
• Hutchison BG, Oxman AD, Shannon HS, Lloyd S, Altmayer CA, Thomas K. Clinical effectiveness of pneumococcal vaccine. Meta-analysis. Can. Fam. Physic.45, 2381–2393 (1999).
   PubMed Web of Science ®Google Scholar
• Moore RA, Wiffen PJ, Lipsky BA. Are the pneumococcal polysaccharide vaccines effective? Meta-analysis of the prospective trials. BMC Fam. Pract.1, 1 (2000).
   PubMedGoogle Scholar
• Cornu C, Yzebe D, Leophonte P, Gaillat J, Boissel JP, Cucherat M. Efficacy of pneumococcal polysaccharide vaccine in immunocompetent adults: a meta-analysis of randomized trials. Vaccine19, 4780–4790 (2001).
   PubMed Web of Science ®Google Scholar
• Mangtani P, Cutts F, Hall AJ. Efficacy of polysaccharide pneumococcal vaccine in adults in more developed countries: the state of the evidence. Lancet Infect. Dis.3, 71–78 (2003).
   PubMed Web of Science ®Google Scholar
• Dear KBG, Andrews R, Holden J, Tatham D. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst. Rev.4, CD000422 (2003).
   Google Scholar
• Melegaro A, Edmunds WJ. The 23-valent pneumococcal polysaccharide vaccine. Part I. Efficacy of PPV in the elderly: comparison of meta-analyses. Eur. J. Epidemiol.19, 353–363 (2004).
   PubMed Web of Science ®Google Scholar
• Fedson DS, Liss C. Precise answers to the wrong question: prospective clinical trials and the meta-analyses of pneumococcal vaccine in elderly and high-risk adults. Vaccine22(8), 927–946 (2004).
   PubMed Web of Science ®Google Scholar
• Moberley SA, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst. Rev.1, CD000422 (2008).
   PubMedGoogle Scholar
• Huss A, Scott P, Stuck AE, Trotter C, Egger M. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ180, 48–58 (2009).
   PubMed Web of Science ®Google Scholar
• Granger R, Walters J, Poole PJ et al. Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease. Cochrane Database Syst. Rev.4, CD001390 (2006). Update in: Cochrane Database Syst. Rev.11, CD001390 (2010).
   Google Scholar
• Walters JA, Smith S, Poole P, Granger RH, Wood-Baker R. Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease. Cochrane Database Syst. Rev.11, CD001390 (2010).
   Google Scholar
• Ya Tseimakh I, Martynenko I, Paraeva S. Prophylactic efficacy of pneumococcal vaccination for chronic obstructive pulmonary disease (COPD). Eur. Respir. J.28(Suppl. 50), S178 (2006) (Abstract P1091).
   Google Scholar
• Teramoto S, Yamamoto H, Yamaguchi Y et al. Clinical efficacy of anti-pneumococcal vaccination in elderly patients with COPD. Presented at: American Thoracic Society International Conference. San Francisco, CA, USA, 18–23 May 2007 (Abstract A137).
   Google Scholar
• Furumoto, Ohkusa Y, Chen M et al. Additive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung disease. Vaccine26, 4284–4289 (2008).
   PubMed Web of Science ®Google Scholar
• Nichol KL, Baken L, Wuorenma J et al. The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease. Arch. Intern. Med.159, 2437–2442 (1999).
   PubMed Web of Science ®Google Scholar
• Lee TA, Weaver FM, Weiss KB. Impact of pneumococcal vaccination on pneumonia rates in patients with COPD and asthma. J. Gen. Intern. Med.22(1), 62–67 (2007).
   PubMed Web of Science ®Google Scholar
• Sumitani M, Tochino Y, Kamimori T, Fujiwara H, Fujikawa T. Additive inoculation of influenza vaccine and 23-valent pneumococcal polysaccharide vaccine to prevent lower respiratory tract infections in chronic respiratory disease patients. Int. Med.47, 1189–1197 (2008).
   PubMed Web of Science ®Google Scholar
• Watanuki Y, Miyazawa N, Kudo M et al. Effects of pneumococcal vaccine in patients with chronic respiratory disease. Eur. Respir. Rev.17(107), 43–45 (2008).
   Google Scholar
• Schembri S, Morant S, Winter JH, MacDonald TM. Influenza but not pneumococcal vaccination protects against all-cause mortality in patients with COPD. Thorax64(7), 567–572 (2009).
   PubMed Web of Science ®Google Scholar
• Vila-Corcoles A, Salsench E, Rodriguez-Blanco T et al. Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in middle-aged and older adults: a matched case–control study. Vaccine27(10), 1504–1510 (2009).
   PubMed Web of Science ®Google Scholar
• Dominguez A, Izquierdo C, Salleras L et al. Working group for the study of prevention of CAP in the elderly. Effectiveness of the pneumococcal polysaccharide vaccine in preventing pneumonia in the elderly. Eur. Respir. J.36(3), 608–614 (2010).
   PubMed Web of Science ®Google Scholar
• Gutierrez F, Masia M, Rodríguez JC et al. Evaluation of the immunochromatographic Binax NOW assay for detection of Streptococcus pneumoniae urinary antigen in a prospective study of community-acquired pneumonia in Spain. Clin. Infect. Dis.36, 286–292 (2003).
   PubMed Web of Science ®Google Scholar
• Rosón B, Fernández-Sabé N, Carratalà J et al. Contribution of a urinary antigen assay (Binax NOW) to the early diagnosis of pneumococcal pneumonia. Clin. Infect. Dis.38, 222–226 (2004).
   PubMed Web of Science ®Google Scholar
• Vila-Corcoles A. Is the pneumococcal polysaccharide vaccine effective in preventing pneumonia? Lancet Infect. Dis.8, 405–406 (2008).
   PubMed Web of Science ®Google Scholar
• Dinleyici EC. Current status of pneumococcal vaccines: lessons to be learned and new insights. Expert Rev. Vaccines9(9), 1017–1022 (2010).
   PubMedGoogle Scholar
• Sisk JE, Moskowitz AJ, Whang W et al. Cost–effectiveness of vaccination against 70 bacteremia among elderly people. JAMA278, 1333–1339 (1997).
   PubMed Web of Science ®Google Scholar
• Evers SM, Ament AJ, Colombo GL et al. Cost–effectiveness of pneumococcal vaccination for prevention of invasive pneumococcal disease in the elderly: an update for 10 Western European countries. Eur. J. Clin. Microbiol. Infect. Dis.26, 531–540 (2007).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb. Mortal. Wkly Rep.59(34), 1102–1106 (2010).
   PubMedGoogle Scholar
• Whitney CG, Farley MM, Hadler J et al. Decline in invasive pneumococcal disease after the introduction of protein–polysaccharide conjugate vaccine. N. Engl. J. Med.348, 1737–1746 (2003).
   PubMed Web of Science ®Google Scholar
• Lexau CA, Lynfield R, Danila R et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA294(16), 2043–2051 (2005).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease – United States, 1998–2003. MMWR Morb. Mortal. Wkly Rep.54, 893–897 (2005).
   PubMedGoogle Scholar
• Grijalva CG, Nuorti P, Arbogast PG, Martin SW, Edwards KM, Griffin MR. Decline in pneumonia admissions after routine childhood immunization with pneumococcal conjugate vaccine in the USA: a time series analysis. Lancet369, 1179–1186 (2007).
   PubMed Web of Science ®Google Scholar
• Hammitt LL, Bruden DL, Butler JC et al. Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal diseases. J. Infect. Dis.193, 1487–1494 (2006).
   PubMed Web of Science ®Google Scholar
• Lockhart SP, Hackell JG, Fritzell B. Pneumococcal conjugate vaccines: emerging clinical information and its implications. Expert Rev. Vaccines5(4), 553–564 (2006).
   PubMed Web of Science ®Google Scholar
• Fry AM, Zell ER, Schuchat A, Butler JC, Whitney CG. Comparing potential benefits of new pneumococcal vaccines with the current polysaccharide vaccine in the elderly. Vaccine21, 303–311 (2002).
   PubMed Web of Science ®Google Scholar
• Jackson LA, Janoff EN. Pneumococcal vaccination of elderly adults: new paradigms for protection. Clin. Infect. Dis.47, 1328–1338 (2008).
   PubMed Web of Science ®Google Scholar
• Musher DM, Sampath R, Rodriguez-Barradas MC. The potential role for protein–conjugate pneumococcal vaccine in adults: what is the supporting evidence? Clin. Infect. Dis.52(5), 633–640 (2011).
   PubMed Web of Science ®Google Scholar
• Scott D, Ruckle J, Dar M, Baker S, Kondoh H, Lockhart S. Phase 1 trial of 13-valent pneumococcal conjugate vaccine in Japanese adults. Pediatr. Int.50(3), 295–299 (2008).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Advisory Committee on Immunization Practices (ACIP). Prevention of pneumococcal disease among infants and children – use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine. MMWR Recommendations Rep.59(RR11), 1–18 (2010).
   PubMedGoogle Scholar
• French N, Gordon SB, Mwalukomo T et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N. Engl. J. Med.362(9), 812–822 (2010).
   PubMed Web of Science ®Google Scholar
• O’Brien KL, Hochman M, Goldblatt D. Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue? Lancet Infect. Dis.7, 597–606 (2007).
   PubMed Web of Science ®Google Scholar
• de Roux A, Schmöle-Thoma B, Siber GR et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin. Infect. Dis.46, 1015–1023 (2008).
   PubMed Web of Science ®Google Scholar
• Dransfield MT, Nahm MH, Han MK et al. Superior immune response to protein-conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med.180, 499–505 (2009).
   PubMed Web of Science ®Google Scholar
• Goldblatt D, Southern J, Andrews N et al. The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50–80 years. Clin. Infect. Dis.49(9), 1318–1325 (2009).
   PubMed Web of Science ®Google Scholar
• Lazarus R, Clutterbuck E, Yu LM et al. A randomized study comparing combined pneumococcal conjugate and polysaccharide vaccination schedules in adults. Clin. Infect. Dis.52(6), 736–742 (2011).
   PubMed Web of Science ®Google Scholar
• Jackson LA, Neuzil KM, Nahm MH et al. Immunogenicity of varying dosages of 7-valent pneumococcal polysaccharide-protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine25, 4029–4037 (2007).
   PubMed Web of Science ®Google Scholar
• Hak E, Grobbee DE, Sanders EA et al. Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. Neth. J. Med.66, 378–383 (2008).
   PubMed Web of Science ®Google Scholar
• Garcia-Suarez Mdel M, Vazquez F, Mendez FJ. Streptococcus pneumoniae virulence factors and their clinical impact: an update. Enferm. Infecc. Microbiol. Clin.24(8), 512–517 (2006).
   PubMed Web of Science ®Google Scholar
• Wu K, Zhang X, Shi J et al. Immunization with a combination of three pneumococcal proteins confers additive and broad protection against Streptococcus pneumoniae infections in mice. Infect. Immun.78(3), 1276–1283 (2010).
   PubMed Web of Science ®Google Scholar
• Giefing C, Meinke AL, Hanner M et al. Discovery of a novel class of highly conserved vaccine antigens using genomic scale antigenic fingerprinting of pneumococcus with human antibodies. J. Exp. Med.205, 117–131 (2008).
   PubMed Web of Science ®Google Scholar
• Cao J, Li D, Gong Y et al. Caseinolytic protease: a protein vaccine which could elicit serotype-independent protection against invasive pneumococcal infection. Clin. Exp. Immunol.156(1), 52–60 (2009).
   PubMed Web of Science ®Google Scholar
• Gianfaldoni C, Maccari S, Pancotto L et al. Sortase a confers protection against Streptococcus pneumoniae in mice. Infect. Immun.77(7), 2957–2961 (2009).
   PubMed Web of Science ®Google Scholar